Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMF biomarker-guided cyclosporine or dupilumab treatment in pediatric atopic dermatitis
NL-OMON23450Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised trial of dupilumab and cyclosporine in atopic dermatitis (AD), sponsored by Erasmus MC. Primary endpoints: Relative reduction in EASI at 6 months and EASI75 without rescue medication at 6 months. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
dupilumabcyclosporine
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON23450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23450.